Apr 23 |
Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround
|
Apr 22 |
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
|
Apr 17 |
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
|
Apr 15 |
Recent 3.8% pullback isn't enough to hurt long-term Krystal Biotech (NASDAQ:KRYS) shareholders, they're still up 437% over 5 years
|
Apr 4 |
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
|
Apr 1 |
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why
|